Media Releases - 19 December 2024
Ozempic supply will remain limited in 2025
Supply of Ozempic will continue to be limited until December 2025, according to the latest advice from Novo Nordisk, the company that manufactures Ozempic.
Ozempic is a semaglutide product approved by the Therapeutic Goods Administration (TGA) for the management of type 2 diabetes that is not adequately managed by other medications, in conjunction with diet and exercise.
A separate semaglutide product, Wegovy, is approved to assist with weight management.
Diabetes Victoria recognises the valid concerns of Victorians living with type 2 diabetes and will continue to advocate for priority access to Ozempic for people living with diabetes.
Novo Nordisk has advised that they are continuing to increase manufacturing capacity, but it will take time to build supply levels to meet global and local demand.
If you have a prescription for Ozempic to manage type 2 diabetes:
• The TGA recommends checking that your regular pharmacy can supply the Ozempic you need ahead of your next dose.
• The TGA is asking health professionals not to prescribe Ozempic to new patients unless there are no suitable alternatives, to conserve supply for patients who are already stabilised on the medicine.
More information about the Ozempic shortage is available on the TGA website.
We encourage anyone who has concerns to speak with a member of their diabetes healthcare team or call the Diabetes Victoria Help Centre on 1300 437 386.
